NCT05905458

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Chengdu Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).

Conditions

• Chronic Hepatitis B

Interventions

Type	Name	Description
DRUG	HRS9950 tablets	HRS9950 tablets, oral, once a week, low dose
DRUG	HRS9950 tablets	HRS9950 tablets, oral, once a week, high dose
DRUG	HRS9950 placebo tablets	HRS9950 placebo tablets, oral, once a week.

Timeline

• Start date: 2023-07-28
• Primary completion: 2024-11-22
• Completion: 2024-11-22
• First posted: 2023-06-15
• Last updated: 2024-12-03

Locations

1 site across 1 country: China